<DOC>
	<DOCNO>NCT01489527</DOCNO>
	<brief_summary>Moffitt Cancer Center Coordinating Center study . The purpose study develop test infrastructure conduct future Phase III vaccine efficacy trial assess trial feasibility , assess human papillomavirus ( HPV ) genotype distribution , data need design Phase III trial . The investigator propose conduct Preparedness study among woman age 16-24 year age reside region South Africa high human immunodeficiency ( HIV ) incidence prevalence . The specific aim study : 1 . Identify , recruit , enroll , randomize cohort HIV negative woman ( 200 per arm , 400 total ) age 16-24 year HPV vaccine 4 type ( HPV 6 , 11 , 16 , 18 [ Gardasil ] ) placebo vaccine . 2 . Determine cervical HPV prevalence type distribution enrollment , cervical lesion prevalence among young female age 16-24 year high risk HIV infection . 3 . Assess rate compliance 3-dose vaccination series</brief_summary>
	<brief_title>Preparedness Study - HPV Vaccine</brief_title>
	<detailed_description>The study vaccine blindly administer supplied Day 1 , Month 2 , Month 6 . Both HPV placebo vaccine identical bottle , treatment code keep lock key . All vaccine inject intramuscularly deltoid muscle member clinical staff . Each participant monitor systemic local reaction 30 minute postvaccination study vaccination adverse effect , include allergic reaction . Vaccine adverse event continue monitor throughout duration study period . Vaccine ship central pharmacy Stellenbosch University store refrigerator monitor maintain 2-8 C prior distribution local storage participate clinical center .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Women age 1624 year age reside region South Africa high HIV incidence prevalence HIV negative ever vaginal intercourse never Papanicolaou smear ( Pap ) test normal Pap test result fully understand study procedure , risk involve study , voluntarily agree participate give write informed consent agree refrain douching/vaginal cleansing use vaginal medication preparation 2 calendar day prior Day 1 visit well future visit include collection cervical specimen agree refrain sexual intercourse 2 calendar day prior Day 1 visit well future visit include collection cervical specimen agree utilize effective contraception sexual intercourse ( exclude rhythm method , withdrawal alone , emergency contraception ) vaccination period . Informed consent procedure females &lt; 18 year age : Informed consent inform assent obtain parents/legal guardian adolescent respectively , prior participation . The consent form include information study individual request consent participant participate study . It emphasize participation voluntary participant free withdraw study stage without disadvantage . An assessment understanding conduct screening ensure consent inform . history severe allergic reaction know allergy vaccine component ( e.g. , aluminum , yeast , BENZONASE ) currently immunocompromised receive marketed HPV vaccine , pregnant lactating</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>24 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Vaccine</keyword>
	<keyword>Placebo</keyword>
	<keyword>sexually transmit infection ( STI )</keyword>
	<keyword>HIV</keyword>
	<keyword>Human Immunodeficiency</keyword>
	<keyword>Gardasil</keyword>
	<keyword>HPV</keyword>
	<keyword>human papillomavirus</keyword>
</DOC>